

Title (en)  
NOVEL MEDICAL USE OF ALDOSTERONE SYNTHASE INHIBITORS ALONE OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS

Title (de)  
NEUE MEDIZINISCHE VERWENDUNG VON ALDOSTERON-SYNTHASE-INHIBITOREN, ALLEINE ODER IN KOMBINATION MIT AT1-REZEPTOR-ANTAGONISTEN

Title (fr)  
COMBINAISON DE COMPOSES ORGANIQUES

Publication  
**EP 1282410 A2 20030212 (EN)**

Application  
**EP 01940317 A 20010410**

Priority  
• EP 0104116 W 20010410  
• US 19674200 P 20000412

Abstract (en)  
[origin: WO0176574A2] The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with (ii) an AT1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.

IPC 1-7  
**A61K 31/00**; **A61K 31/4196**; **A61K 31/437**; **A61K 31/5685**; **A61K 45/06**

IPC 8 full level  
**A61K 31/00** (2006.01); **A61K 31/41** (2006.01); **A61K 31/415** (2006.01); **A61K 31/4196** (2006.01); **A61K 31/437** (2006.01); **A61K 45/06** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/4709** (2006.01); **A61K 31/549** (2006.01); **A61K 31/565** (2006.01); **A61P 3/00** (2006.01); **A61P 3/04** (2006.01); **A61P 3/06** (2006.01); **A61P 3/10** (2006.01); **A61P 5/14** (2006.01); **A61P 9/04** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 13/12** (2006.01)

CPC (source: EP KR)  
**A61K 31/00** (2013.01 - EP); **A61K 31/41** (2013.01 - EP); **A61K 31/415** (2013.01 - EP); **A61K 31/4196** (2013.01 - EP); **A61K 31/435** (2013.01 - KR); **A61K 31/437** (2013.01 - EP); **A61K 31/44** (2013.01 - EP); **A61K 31/565** (2013.01 - EP); **A61K 31/5685** (2013.01 - EP); **A61P 3/00** (2018.01 - EP); **A61P 3/04** (2018.01 - EP); **A61P 3/06** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 5/14** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/04** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 9/12** (2018.01 - EP); **A61P 13/00** (2018.01 - EP); **A61P 13/12** (2018.01 - EP)

C-Set (source: EP)  
1. **A61K 31/565 + A61K 31/44**  
2. **A61K 31/565 + A61K 31/415**  
3. **A61K 31/565 + A61K 31/41**  
4. **A61K 31/44 + A61K 31/415**  
5. **A61K 31/415 + A61K 31/415**  
6. **A61K 31/41 + A61K 31/41**  
7. **A61K 31/44 + A61K 31/41**  
8. **A61K 31/415 + A61K 31/41**  
9. **A61K 31/41 + A61K 2300/00**  
10. **A61K 31/415 + A61K 2300/00**  
11. **A61K 31/44 + A61K 2300/00**  
12. **A61K 31/565 + A61K 2300/00**

Citation (examination)  
THE MERCK MANUAL OF DIAGNOSIS AND THERAPY; MERCK AND RESEARCH LABORATORIES, 1999, WHITEHOUSE STATION, N.J. USA

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0176574 A2 20011018**; **WO 0176574 A3 20020425**; AR 032316 A1 20031105; AU 2001273938 B2 20050303; AU 7393801 A 20011023; BR 0110079 A 20021231; CA 2405895 A1 20011018; CN 1422152 A 20030604; EP 1282410 A2 20030212; HU P0301335 A2 20030828; HU P0301335 A3 20060228; IL 152081 A0 20030529; JP 2003530343 A 20031014; KR 20020089437 A 20021129; MX PA02010091 A 20030212; NO 20024920 D0 20021011; NO 20024920 L 20021127; NZ 521855 A 20041029; PE 20020082 A1 20020221; PL 358459 A1 20040809; RU 2002129569 A 20040327; SK 14612002 A3 20030502; ZA 200208204 B 20031014

DOCDB simple family (application)  
**EP 0104116 W 20010410**; AR P010101698 A 20010410; AU 2001273938 A 20010410; AU 7393801 A 20010410; BR 0110079 A 20010410; CA 2405895 A 20010410; CN 01807917 A 20010410; EP 01940317 A 20010410; HU P0301335 A 20010410; IL 15208101 A 20010410; JP 2001574092 A 20010410; KR 20027013486 A 20021008; MX PA02010091 A 20010410; NO 20024920 A 20021011; NZ 52185501 A 20010410; PE 2001000328 A 20010410; PL 35845901 A 20010410; RU 2002129569 A 20010410; SK 14612002 A 20010410; ZA 200208204 A 20021011